On September 8, Sandoz announced plans to invest about 300 million US dollars to build a new biosimilar API production facility in Ljubljana, Slovenia, which is expected to be put into operation in 2029. The new facility will use batch technology for disposable supplements to increase the production capacity of 8,000 liters of biopharmaceutical APIs through 4 reactors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.